{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T05:42:00Z","timestamp":1740980520233,"version":"3.38.0"},"reference-count":5,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T00:00:00Z","timestamp":1133395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2005,12]]},"abstract":"<jats:p> Topical application of 5-fluorouracil (5-FU) is one of the most effective clinical strategies available to treat actinic keratosis (AK). During treatment, an apparent toxic skin reaction occurs before dermal quiescence ensues. We report a case of a typical flare of AK in a woman treated with capecitabine for advanced breast cancer. <\/jats:p>","DOI":"10.1191\/1078155205jp163cr","type":"journal-article","created":{"date-parts":[[2006,3,16]],"date-time":"2006-03-16T21:26:40Z","timestamp":1142544400000},"page":"151-153","source":"Crossref","is-referenced-by-count":8,"title":["Actinic keratosis and capecitabine therapy"],"prefix":"10.1177","volume":"11","author":[{"given":"Gerald M","family":"Higa","sequence":"first","affiliation":[{"name":"Department of Medicine, Section of Hematology\/Oncology, Mary Babb Randolph Cancer Center, West Virginia University, Morgantown, WV, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodney F","family":"Kovach","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Dermatology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jame","family":"Abraham","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Hematology\/Oncology, Mary Babb Randolph Cancer Center, West Virginia University, Morgantown, WV, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2005,12,1]]},"reference":[{"key":"atypb1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.1995.tb00132.x"},{"key":"atypb2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1969.tb107944.x"},{"key":"atypb3","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(97)70265-2"},{"key":"atypb4","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(97)70137-3"},{"key":"atypb5","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.140.3.367"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1191\/1078155205jp163cr","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1191\/1078155205jp163cr","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T14:05:10Z","timestamp":1740924310000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1191\/1078155205jp163cr"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12]]},"references-count":5,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["10.1191\/1078155205jp163cr"],"URL":"https:\/\/doi.org\/10.1191\/1078155205jp163cr","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"type":"print","value":"1078-1552"},{"type":"electronic","value":"1477-092X"}],"subject":[],"published":{"date-parts":[[2005,12]]}}}